Worm.com

CORPORATE IT UPDATE-(C)1995-2008 M2 COMMUNICATIONS LTD

Internet security solutions provider Symantec Corp (Nasdaq: SYMC) announced on Wednesday (21 May) that the state of Missouri, USA, has selected Symantec Enterprise Vault as its e-mail archiving platform, ensuring the security and retention of electronic communications in accordance with governor Matt Blunt’s directive to archive government e-mails.

According to the company, Enterprise Vault enables the state to comply with legal discovery requirements and information access policies such as open-records requests. In addition, the state plans to utilize the solution to improve e-mail storage capabilities, at the same time simplifying e-mail system management.

The state of Missouri’s licensing agreement for Enterprise Vault expands the level of standardization on Symantec solutions. The state already uses other Symantec solutions, including Symantec AntiVirus, Symantec Mail Security, Gateway Security, Ghost Solution Suite, pcAnywhere, and Backup Exec, the company claims.

No financial details were disclosed.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2008 M2 Communications Ltd.
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

The European Commission’s Decision and Global Demand Demonstrates Market Opportunities for Solutions Against H5N1 Strain of Bird Flu

eFoodSafety’s Citroxin[TM] Has Shown 68% Kill Rate Against H5N1 in Chick Embryos

SCOTTSDALE, Ariz. — eFoodSafety.com, Inc. (OTCBB: EFSF, www.efoodsafety.com) applauds the European Commission’s marketing authorization in the European Union of GlaxoSmithKline’s ("GSK") H5N1 pre-pandemic bird flu vaccine Prepandrix[TM]. eFoodSafety, which is also dedicated to developing solutions aimed at combating the virulent H5N1 strain of bird flu, commends the European Commission for raising global awareness of the influenza pandemic and allowing for the advancement of technologies designed to address potential human threats relating to this deadly virus. The company’s proprietary product, Citroxin[TM], an environmentally safe sporicidal product formulated entirely of food-grade components, has shown 68% efficacy in eradicating the H5N1 strain of bird flu in chick embryos.

"The European Commission’s marketing approval of GlaxoSmithKline’s Prepandrix signifies tremendous progress in global efforts to fight bird flu in humans," says Patricia Gruden, CEO of eFoodSafety. "eFoodSafety has been committed to eradicating the avian flu through its development of Citroxin and we have long believed that H5N1 should be addressed in order to prevent a potential pandemic. This week’s news further supports our contention that bird flu is a global social health concern, and that, given the proper solutions, we can mitigate potential risks to humans."

A World Health Organization (WHO) action plan notes that over the past decade H5N1 has successfully "crossed the species barrier" from animals to humans, a shift that it considers "[poses] an imminent pandemic threat." The several hundred human cases of H5N1 since 2003 have often resulted in fatality; as the number of cases continues to increase, countries around the world are spending more money to help avoid a global pandemic. As reported by the Wall Street Journal, Switzerland and Finland have already placed orders for GSK’s vaccine, and other countries are considering the same, in order to amass a cautionary supply in the event of an outbreak or pandemic. The World Bank projects that costs associated with fighting avian flu will range between $1.2 and $1.5 billion by 2009.

In addition to the human implications of the virus, bird and farm animals are also at risk of infection. As an early entrant in the market, eFoodSafety recognizes potential to use its Citroxin formula in the mass market as a solution against the virulent influenza. After positive initial results for Citroxin’s ability to eradicate H5N1 in chick embryos, eFoodSafety has planned to conduct additional rounds of testing in live animals affected with forms of flu that closely resemble human strains of the disease. The company’s initial tests were conducted at Chulalongkorn University in Thailand, one of only two labs in Asia that is used by the U.S. Centers of Disease Control to conduct research on treatments of H5N1. Subsequent rounds of testing are planned by the company to be conducted at a university in the United States that has been nationally recognized for its field studies in bird flu.

About eFoodSafety.com

eFoodSafety.com, Inc., based in Scottsdale, Arizona, is dedicated to improving health conditions around the world through its innovative technologies. Among eFoodSafety products currently available:

Citroxin[TM]: an environmentally safe sporicidal product, formulated entirely of food-grade components that kills six major bacteria as well as avian influenza.

Cinnergen[TM]: a clinically researched, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism. (www.cinnergendirect.com)

Cinnechol[TM]: a multi-faceted nutritional supplement specifically designed to naturally promote healthy cholesterol and triglyceride levels without causing any side effects, as well as enhance overall cardiovascular health. (www.cinnechol.com)

PurEffect[TM]: an anti-acne skin care system.

Immune Boost Bar[TM]: a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body’s immune system and is available in four delicious flavors: chocolate, oatmeal-raisin, chocolate mint and peanut butter. (www.immuneboost.com)

Talsyn[TM]: a product that has been clinically proven to facilitate and improve the appearance, redness and strength of scars.

Please visit the company’s website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking statements." Such forward-looking statements are sometimes identified by words such as "intends," "anticipates," "believes," "expects," and "hopes." The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

In 2007, the U.S. Center for Disease
Control recorded over 3,500 human cases of West Nile Virus resulting in 109
deaths. Eastern Equine Encephalitis and Dog Heartworm — both spread by
mosquitoes — pose significant and continued threats this year and recent
reports from the National Institute of Allergy and Infectious Diseases
state that the appearance of Dengue Fever in the U.S. is a real
possibility.

These major health concerns should encourage homeowners to get a jump on
protecting their backyards before female mosquito breeding cycles begin.
According to the American Mosquito Control Association, one female mosquito
can lay 450 eggs at a time, and she may do this three times in her
life. By the fourth generation of offspring, this female could yield
nearly 50 billion mosquitoes, assuming 70 percent survive to adulthood.
[For more mosquito facts and "survival guide" tips, visit FarewellMosquitoes.com .]

To combat these pests, Kaz, Inc., a leading global manufacturer of quality
healthcare and home comfort products, now offers homeowners the Stinger
family of Mosquito Vacuums Home Depot and Lowe’s stores nationwide.
Mosquito Vacuums provide long-term family protection and backyard comfort
using propane-fueled, insect control technology developed to reduce
annoying biting mosquitoes and the risk of dangerous mosquito-borne
illnesses.

According to Kristin Anderson, Stinger Brand Manager for Kaz, “These
mosquito devices are designed to provide an effective, long-term solution
to reducing backyard mosquito populations, and combines proven
mosquito-attracting science with powerful vacuum technology and a reliable
design. We’ve done the research to ensure homeowners get the
highest-quality mosquito control at an affordable price.”

Chemical sprays, candles and lotions offer only temporary and potentially
harmful relief from mosquitoes, but the Stinger Mosquito Vacuum is odorless
and silent; providing continuous 24-hour protection from mosquitoes, black
flies, gnats, and no-see-ums.

Created by engineers with mosquito control device expertise, independent
tests show that Mosquito Vacuum outperforms the competition because of the
product’s unique combination of carbon dioxide (CO2), heat, moisture and
exclusive EPA-approved multi-scent bait, making Mosquito Vacuum more
effective than any other trapping device sold at retail.

Burning the same propane as barbeque grills and emitting the same CO2 as a
small dog, the Mosquito Vacuum creates an alluring bio-signature similar to
a living host, mimicking human breath and body heat to attract and kill
hungry female mosquitoes in up to
one-acre range. Combining CO2, heat, moisture, visual cues, and scent, the
Mosquito Vacuum lures female mosquitoes into the inescapable bug basket
with noticeable results in a one-acre range within 30 days.

Headquartered in Southborough, Mass., Kaz, Inc. ( www.kaz.com ) is a trusted
and dedicated healthcare and home comfort product manufacturer. Kaz has
offered high-quality home environment products since founder Max Katzman’s
invention of the world’s first electric vaporizer 70 years ago. Today, the
family business manufactures and distributes innovative products worldwide.

Embedded Video Available

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=765062
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=765066
Embedded Video Available: http://www2.marketwire.com/mw/release_html_b1?release_id=399775

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Julie Dennehy
508-533-8311
Email Contact

Information provided by: Findarticles.com

AMSTERDAM, The Netherlands, May 22 /PRNewswire-FirstCall/ — Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from La Sapienza University in Rome, Italy, to their advanced small nuclear RNA (snRNA)-based exon-skipping technology for the treatment of Duchenne muscular dystrophy (DMD). The combination with AMT’s proprietary adeno-associated virus (AAV) gene therapy platform potentially makes up a long-term treatment for this seriously debilitating disease with a single administration of the product.

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy, caused by mutations in the dystrophin gene (essential for muscle function) is a severely debilitating neuromuscular disease. It affects young children, is progressive and leads to death in young adulthood. In the USA and Europe about 120,000 people suffer from it. Today, there is no treatment to prevent the fatal outcome.

The group of Prof. Irene Bozzoni at La Sapienza has done seminal work to develop a treatment for DMD. Using adeno-associated viral vectors, AMT’s gene therapy platform of choice, and an exon-skipping snRNA program Bozzoni and co-workers demonstrated long term systemic and therapeutic effect in animals after a single administration[1]. One of the important advantages of the Bozzoni technology is that a single systemic delivery of the AAV vector containing the required antisense RNA-coding construct will result in long-term treatment of Duchenne muscular dystrophy.

Formalizing relationship with leading RNA research group of prof. Irene Bozzoni

Ronald Lorijn, CEO of AMT said: "We are very excited to have inlicenced an exciting therapeutic approach, which has shown to provide a life-long cure in rodents suffering from Duchenne’s disease. In Duchenne’s disease in particular the combined application of snRNA and AAV vectors has shown tremendous promise. Access to La Sapienza’s RNA technology perfectly complements our gene and vector therapy platform. It adds a project to AMT’s R&D pipeline that will start its pre-clinical phase this year."

Exon skipping in DMD

Exon skipping is a technology to neutralize genetic defects by preventing the faulty parts of the gene being used. At the cellular level, a molecule called messenger RNA (mRNA) reads off (transcribes) the protein instructions from the gene. It then transports these instructions to the ribosomes in the cell where the protein is assembled. Messenger RNA is not a transcript of the complete gene sequence, but only of the exons, which are the sections of the gene that code for a portion of the protein. If one of the exons contains an error, this process may be halted, and the production of the full-length dystrophin protein cannot take place. However, when the faulty exon is eliminated (i.e. skipped), protein synthesis does take place and leads to a functional, albeit shorter, dystrophin protein. By using the exon-skipping technique the mutated exons in the dystrophin mRNA that contain errors are "skipped" and as a result the muscle cells are able to produce functional dystrophin protein.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT’s proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT’s business, including, but not limited to, the timely commencement and success of AMT’s clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT’s products, effectiveness of AMT’s marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT’s initial public offering on June 20, 2007, and AMT’s public announcements made from time to time.

Information provided by: Findarticles.com

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ — Novavax, Inc. today announced that it has created a new proprietary process to develop a vaccine candidate against Severe Acute Respiratory Syndrome (SARS). The company also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of SARS vaccine candidates using Novavax’s virus-like particle (VLP) technology.

"Until now, it has been difficult to produce VLP vaccine candidates against SARS and other complex infectious disease targets because many of these biological structures do not assemble efficiently," said Dr. Gale Smith, Vice President, Vaccine Development. "Our new proprietary process uses select components of SARS and other structural proteins that combine with cell membranes to form distinctive SARS coronavirus nanoparticles, which are nearly identical to the human SARS virus but lack the genetic material needed to replicate and cause disease."

"This new approach to create VLPs will allow us to continue our work to develop a SARS vaccine candidate and expand the potential applications of our vaccine technology to a broad range of infectious diseases around the world," said Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus and was first reported in Asia in February 2003. According to the World Health Organization (WHO), subsequent to the 2003 breakout, over 8,000 people were infected, with 774 reported deaths. While there is currently no known reported SARS transmission globally, WHO and other such agencies continue to monitor the SARS situation on a global basis as health officials remain concerned that SARS or similar disease could reemerge.

The SARS VLP program is conducted under an NIH grant. Novavax does not have the commercial rights to this product candidate.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing a new, efficient manufacturing solution. Additional information about Novavax is available at http://www.novavax.com/ and in the Company’s various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company’s ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; the Company may not have the personnel or capital resources to expand its product candidate pipeline; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax’s business, financial conditions and results of operations, is contained in Novavax’s filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov/. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

CONTACT: Tricia J. Richardson of Novavax, Inc., +1-240-268-2031

Web site: http://www.novavax.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

- Lead Candidate, RDEA806, Demonstrated No Reproductive Toxicity in Preclinical Study -

- RDEA427 Selected as Clinical Candidate, Demonstrated a 40 Hour Half-Life with Potential for Once Daily Oral Dosing -

SAN DIEGO, May 22 /PRNewswire-FirstCall/ — Ardea Biosciences, Inc. today announced preclinical data on its lead non-nucleoside reverse transcriptase inhibitor (NNRTI) candidate, RDEA806, demonstrating no reproductive toxicity. In addition, novel second-generation NNRTI, RDEA427, was selected as a development candidate for the potential treatment of the human-immunodeficiency virus (HIV), the causative agent of AIDS.

Animal reproductive toxicity studies recently completed with RDEA806 have demonstrated no effects on male or female fertility or on early embryonic development at all tested doses. These results are in contrast to the fetal malformations reported in other NNRTI animal reproductive toxicity studies.

Exploratory human testing (Phase 0) of RDEA427 was recently completed in which micro-doses of the compound were administered to healthy volunteers. Preliminary pharmacokinetic data from this study, produced by Vitalea Science, Inc. using Accelerator Mass Spectrometry (AMS) technology, demonstrated that RDEA427 has a half-life of approximately 40 hours, which could permit once daily oral dosing.

"The ability to use RDEA806 in women, without the risk of birth defects, is a major advantage over the current first-line NNRTI. Women make up 26% of HIV/AIDS diagnosed patients in the United States, and an even larger percent of infected patients worldwide. These preclinical data for RDEA806 further strengthen its impressive product profile," said Barry D. Quart, PharmD, Ardea Biosciences’ President and CEO. "In addition, the excellent preclinical properties of RDEA427 and its long half-life in humans make it the perfect candidate to progress into clinical testing. Developing both RDEA806 and RDEA427 in tandem is consistent with our business strategy of keeping Ardea’s pipeline full of novel compounds in areas that are underserved by current treatment options. We are on track to begin a Phase 1 trial with RDEA427 later this year, and expect to initiate a Phase 2b trial with RDEA806 in the third quarter of this year."

About RDEA806 and RDEA427

RDEA806 and RDEA427 are novel, structurally different NNRTIs for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 and RDEA427 may have important competitive advantages. These include: the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs. RDEA806 reproductive toxicity data indicates that future studies, including Ardea’s planned Phase 2b trial, would likely include women of child-bearing age in anti-retroviral naive HIV-infected patients.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Information provided by: Findarticles.com

Webinar to Unveil Any-Point-in-Time Recovery Strategies

SOUTHBOROUGH, Mass. — Double-Take([R]) Software (NASDAQ: DBTK) will showcase its latest innovation, TimeData([R]), in an upcoming webinar on May 29, 2008. TimeData is an any-point-in-time recovery solution that allows customers to recover lost or corrupted data at the file level. This, used in combination with Double-Take([R]), offers a complete data protection strategy that ensure companies can easily recover from the next disaster - regardless of the size.

Webinar participants will learn how to leverage TimeData technology to quickly and easily recover from common operational issues such as viruses, data corruption, deleted files or other human errors. Operational recovery is a critical component in any business continuity plan and should be designed in parallel with larger disaster recovery planning.

The TimeData webinar will discuss:

* The features of TimeData continuous data protection technology and learn how TimeData protects data in an operational environment

* How Double-Take, in combination with TimeData, offers complete data protection against disasters of all sizes

* How to leverage TimeData to recover from loss, corruption or security breaches within minutes of impact

Webinar Information: To register for the webinar, click here.

Date: Thursday, May 29, 2008

Time: 1pm - 2pm E.T.

Bob Roudebush, director of solutions engineering, Double-Take Software

With over a decade of IT industry experience with companies like Microsoft and multiple industry certifications, Bob works with the Double-Take Software sales force, sales engineers, customers and prospects to position and promote Double-Take Software solutions. Through Bob’s efforts, Double-Take Software has been widely acknowledged as a leader in easy-to-use software for recoverability. Bob possesses a deep understanding of technology and the data protection market as a whole. He has also been named a Microsoft MVP Award winner for 2006 through 2008.

About Double-Take[R] Software

Headquartered in Southborough, Massachusetts, Double-Take[R] Software (Nasdaq: DBTK) is a leading provider of affordable software for recoverability, including continuous data replication, application availability and system state protection. Double-Take Software products and services enable customers to protect and recover business-critical data and applications such as Microsoft Exchange, SQL, and SharePoint in both physical and virtual environments. With its unparalleled partner programs, technical support, and professional services, Double-Take Software is the solution of choice for more than ten thousand customers worldwide, from SMEs to the Fortune 500. Information about Double-Take Software’s products and services can be found at www.doubletake.com.

This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases that say Double-Take or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All forward-looking statements are inherently speculative, and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in forward-looking statements. These risks and uncertainties include those set forth from time to time in our filings with the Securities and Exchange Commission. We are under no obligation, and do not undertake any duty, to update these forward looking statements at any time.

(c) Double-Take Software. All rights reserved. Double-Take, GeoCluster, Double-Take for Virtual Systems, and NSI are registered trademarks of Double-Take Software, Inc. Balance and Double-Take ShadowCaster are trademarks of Double-Take Software, Inc. TimeData is a registered trademark of Double-Take Software Canada, Inc. TimeData logo is a trademark of Double-Take Software Canada, Inc. Microsoft, Windows, and the Windows logo are trademarks or registered trademarks of Microsoft Corporation in the United States and/or other countries. All other trademarks are the property of their respective companies.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

BUJUMBURA (AFP) — HIV/AIDS prevalence in the small central African nation of Burundi rose to 4.2 percent last year from 3.5 percent in 2002, health officials said Thursday.

The increase is due to “the situation in our country which is emerging from war, poverty and strong beliefs (among people) in the countryside..,” said Speciose Baransata, the deputy minister in charge of combating the disease.

Of its seven million people, around 250,000 are living with the virus and only some 11,000 have access to treatment.

“We call on the government to truly re-commit itself …

Information provided by: Findarticles.com

DHAKA (AFP) — Bangladesh reported its first confirmed case of human bird flu on Thursday, but said the 16-month-old victim had now recovered from the virus.

The baby boy from a Dhaka slum was diagnosed with the H5N1 strain of the disease in January, but this was only confirmed by a US laboratory this week, the government said.

“There is no reason to panic. The child contracted the H5N1 bird flu virus in January but we only got confirmation from the CDC (US Centers for Disease Control) on Wednesday it was a human bird flu case,” said senior government official Saluddin Khan.

Earlier, a health ministry official had said the child was still in hospital.

But Khan, who works for the livestock ministry and is coordinating Bangladesh’s battle against bird flu, said the boy “has now made a complete recovery.”

Khan said Bangladesh’s fight against the virus …

Information provided by: Findarticles.com